Evelo Biosciences, Inc. (EVLO)

0.0495 +0.0038 (+8.32%) At close: 03:58PM EDT

Evelo Biosciences, Inc.

620 Memorial Drive
5th Floor
Cambridge, MA 02139
United States
617 577 0300
https://www.evelobio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 66

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Craig R. Jalbert CIRA	President, Secretary, Principal Executive, Financial and Accounting Officer & Director	N/A	N/A	1962
Dr. Chun Zhang Ph.D.	Chief Technical Operations & Quality Officer	N/A	N/A	N/A
Dr. Mark Bodmer Ph.D.	Chief Scientific Officer and President of Research & Development	668.8k	N/A	1958
Ms. Jessica Cotrone	VP & Head of Communications	N/A	N/A	N/A
Ms. Leslie Wardwell-Scott Ph.D.	VP and Head of Corporate Development & Strategic Integration	N/A	N/A	N/A
Dr. Andrea Itano Ph.D.	Head of Research	N/A	N/A	N/A
Dr. Duncan McHale M.D., MBBS, Ph.D.	Chief Medical Officer	661.97k	N/A	1967
Mr. Douglas Maslin	Senior Director & Immunology Clinical Lead	N/A	N/A	N/A

Amounts are as of 31 December 2017, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Evelo Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.